A kind of pharmaceutical composition for treating Parkinson's syndrome and its preparation method and application

Abstract

The invention discloses a pharmaceutical composition, which is a preparation prepared from raw materials in the following weight proportions: 6-60 parts of rehmannia glutinosa, 5-50 parts of Gastrodia elata, and 1-15 parts of scorpion. The invention also provides the preparation method and application of the pharmaceutical composition. Pharmacological tests have proved that the pharmaceutical composition of the present invention can significantly improve the symptoms of Parkinson's syndrome, and can effectively treat Parkinson's syndrome; there is toxicity in the scorpion in the prescription, and its toxic and side effects can be reduced after the compatibility of the present invention. The pharmaceutical composition of the present invention The medicine is accurate and appropriate, the cost is low, the preparation method is simple, and the preparation method is suitable for large-scale production.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating Parkinson's syndrome. Background technique [0002] Parkinson's disease (PD) is a common movement disorder in middle-aged and elderly people. It is characterized by the degeneration and loss of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies. The clinical manifestations are resting tremor, slow movement, muscle rigidity and posture Abnormal gait, etc. Parkinson's syndrome is one of the difficult diseases identified by the World Health Organization. The prevalence rate of the elderly population over 65 years old is 2%. , a huge burden on society. [0003] At present, the drugs for the treatment of Parkinson's syndrome in Western medicine are generally compound levodopa preparations, dopamine receptor agonists, anticholinergic preparations or amantadine, etc., but long-term frequent or large-scale use will cause obvious central adverse reactions. For examp...

AI Technical Summary

Problems solved by technology

[0003] At present, the drugs for the treatment of Parkinson's syndrome in Western medicine are generally compound levodopa preparations, dopamine receptor agonists, anticholinergic preparations or amantadine, etc., but long-term frequent or large-scale use will cause obvious central adverse reactions. For example: diminished efficacy or worsening at the end of the dose, fluctuations in symptoms between sudden relief and aggravation, dyskinesias, episodes of freezing or psychiatric symptoms, etc.

Images